• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Aripiprazole in Depression: The Right Dose

Aripiprazole in Depression: The Right Dose

September 25, 2022
Richard Moldawsky, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Richard Moldawsky, MD. Dr. Moldawsky has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Furukawa Y et al, Br J Psychiatry 2022;221(2):440–447

STUDY TYPE: Meta-analysis of randomized controlled trials

Aripiprazole is FDA approved for antidepressant augmentation, and although it is the best-studied atypical antipsychotic for this condition, practitioners have not yet nailed down what dose to prescribe. Guidelines recommend anywhere from 2 to 15 mg/day, but higher doses bring additional risks like akathisia, sedation, and metabolic problems. This meta-analysis aimed to find the optimal dose range.

The authors found 10 double-blind, placebo-controlled, randomized studies in which aripiprazole was added to an SSRI or SNRI antidepressant in patients with treatment-resistant depression. The definition of treatment resistance varied among the studies, which required an inadequate response to 1–3 antidepressant trials and lasting at least 6–12 weeks. Patients with other psychiatric and substance use disorders were excluded, as were any who had received electroconvulsive therapy in the last 10 years or had been on adjunctive antipsychotics in the three weeks before starting aripiprazole.

This yielded 2,625 patients, 55% female. Over half the studies took place in North America and about a third were conducted in Japan. Some studies compared augmentation with aripiprazole using a fixed-dose schedule and others allowed flexible dosing. Trials lasted six to eight weeks. Doses ranged from 2 to 20 mg/day. Reduction in the Montgomery-Åsberg Depression Rating Scale was the main outcome measure. Tolerability (dropouts due to adverse effects) and acceptability (dropouts for any reason) were also tracked.

The main finding was that efficacy was associated with doses between 2 and 5 mg, with no additional benefits at higher doses. Aripiprazole 4 mg resulted in a 36% improvement compared with 23% on placebo. The odds ratio of response gradually increased as the dose increased from 2 mg (1.46) to 4 mg (1.87), then leveled off at 5 mg (1.91). Doses beyond 5 mg were well tolerated but didn’t add clinical benefit.

One limitation is that the analysis involved multiple studies with varied doses that were not designed to test the hypothesis at hand. It is possible that some patients will do better at higher doses of adjunctive aripiprazole, but it is difficult to say who they are.

CARLAT TAKE

When using aripiprazole for antidepressant augmentation, 2–5 mg is the ideal range.

General Psychiatry
KEYWORDS aripiprazole depression
    Richard Moldawsky, MD

    Buprenorphine versus Methadone for Prescription Opioid Use Disorder

    More from this author
    www.thecarlatreport.com
    Issue Date: September 25, 2022
    SUBSCRIBE NOW
    Table Of Contents
    A Diet for ADHD
    Understanding the Varieties of Depression
    The Benzodiazepine-Stimulant Combo: What Could Go Wrong?
    Treatment-Resistant Depression
    Can CBD Work for PTSD?
    Aripiprazole in Depression: The Right Dose
    A Single Prescriber Reduces Risk of Overdose in Patients on Opioid and Benzodiazepine
    CME Post-Test - Depression, TCPR, October/November 2022
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.